PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Specialty ketamine company PharmaTher Holdings Ltd.
Australia’s Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions
As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the
Awakn’s Ketamine Treatment For Alcohol Use Disorder Awarded UK’s Fast-Track Status
Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) to treat severe AUD.
Psyched: Australia Legalizes Psychedelics Therapy, BC’s Decrim, State Bills, Millions For Trials & Clinics
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD
Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as post-traumatic stress disorder and psilocybin for treatment-resistant depression.
EXCLUSIVE: Fox Rothschild Cannabis Attorney Analyzes Psychedelics Regs And Changing Public Perceptions
(Part one of a three-part series)
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.
This Psychedelic-Assisted Therapy Study Offers Therapists Experience With Magic Mushroom Tea
Psychedelic-assisted therapy provider, Numinus Wellness Inc.
EXCLUSIVE: Next-Generation Psychedelics, MEAI – The Road Ahead
(Part four of a four-part series)
See previous parts of the series:
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction